123 310

Cited 0 times in

Effects of Pamidronate Treatment on Osteogenesis Imperfecta

Other Title
골형성부전증 환자에서 파미드로네이트의 치료 효과
이, 승원; 김, 현주; 조, 재현; 이, 형숙; 정, 연무; 김, 대중; 이, 관우; 정, 윤석
Journal of Korean Society of Endocrinology, 19(5):485-491, 2004
Journal Title
Journal of Korean Society of Endocrinology; 대한내분비학회지
Background:Osteogenesis imperfecta (OI) is a congenital disorder of type I collagen, with variable phenotypes, due to increased bone fragility and low bone mass. Previous pharmacological treatments for OI have been attempted with calcitonin and growth hormone but with little beneficial effects. Recently, Glorieux reported the beneficial effects of bisphosphonates in OI.

Methods:In this study, the effects of pamidronate treatment were evaluated in 9 patients with OI. All patients received intravenous pamidronate infusions, which was dose adjusted according to the patients’ age. The outcome measures included the biochemical bone markers; serum alkaline phosphatase, urine deoxy-pyridinoline, urine Ca/Cr ratio, and bone mineral density (BMD).

Results:Serum alkaline phosphatase, urine deoxypyridinoline, and urine Ca/Cr ratio were slightly decreased after 1 year of therapy, although these changes were not statistically significant. The BMDs of the lumbar spine and proximal femur were significantly increased after 1-year of pamidronate treatment. No fractures were reported during the 1 year treatment periods.

Conclusions:Pamidronate treatment had an effect on the BMD in osteogenesis imperfecta, probably due to decreasing bone resorption
Osteogenesis imperfectaPamidronateBiochemical bone markerBone mineral density
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Endocrinology & Metabolism
Full Text Link
Files in This Item:
Journal of Korean Society of Endocrinology_19(5)_485-491.pdfDownload
RIS (EndNote)
XLS (Excel)


해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.